Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 1995 Nov;13(11):2856-9.

Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.

Author information

  • 1Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.

Abstract

PURPOSE:

Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia.

PATIENTS AND METHODS:

Seventy patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with cancer anorexia and/or cachexia (defined by a weight loss of > or = 5 lb in the preceding 2 months or a caloric intake < 20 kcal/kg/d) were stratified and then randomly assigned to receive pentoxifylline or identical-appearing placebo tablets in a double-blind fashion. Patients' weights were monitored and patient questionnaires were used to assess appetite, toxicity, and perception of benefit.

RESULTS:

Pentoxifylline failed to improve the appetites of study patients. Pentoxifylline did not appear to cause any toxicity.

CONCLUSION:

This study failed to demonstrate any benefit of pentoxifylline at this dose and schedule as therapy for cancer anorexia and/or cachexia.

PMID:
7595749
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk